167 related articles for article (PubMed ID: 10369477)
1. Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats.
Cleton A; Mazee D; Voskuyl RA; Danhof M
Br J Pharmacol; 1999 May; 127(1):227-35. PubMed ID: 10369477
[TBL] [Abstract][Full Text] [Related]
2. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam.
Albrecht S; Ihmsen H; Hering W; Geisslinger G; Dingemanse J; Schwilden H; Schüttler J
Clin Pharmacol Ther; 1999 Jun; 65(6):630-9. PubMed ID: 10391668
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol.
Tuk B; van Gool T; Danhof M
J Pharmacokinet Pharmacodyn; 2002 Jun; 29(3):235-50. PubMed ID: 12449497
[TBL] [Abstract][Full Text] [Related]
4. Effect of 7-day exposure to midazolam on electroencephalogram pharmacodynamics in rats: a model to study multiple pharmacokinetic-pharmacodynamic relationships in individual animals.
Laurijssens BE; Greenblatt DJ
J Pharm Pharmacol; 2002 Jan; 54(1):77-86. PubMed ID: 11829133
[TBL] [Abstract][Full Text] [Related]
5. Adaptive changes in the pharmacodynamics of midazolam in different experimental models of epilepsy: kindling, cortical stimulation and genetic absence epilepsy.
Cleton A; Voskuyl RA; Danhof M
Br J Pharmacol; 1998 Oct; 125(4):615-20. PubMed ID: 9831893
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats.
Hovinga S; Stijnen AM; Langemeijer MW; Mandema JW; van Bezooijen CF; Danhof M
Br J Pharmacol; 1992 Sep; 107(1):171-7. PubMed ID: 1422570
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration.
Mandema JW; Tukker E; Danhof M
Br J Pharmacol; 1991 Mar; 102(3):663-8. PubMed ID: 1364836
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients.
Swart EL; Zuideveld KP; de Jongh J; Danhof M; Thijs LG; Strack van Schijndel RM
Eur J Clin Pharmacol; 2006 Mar; 62(3):185-94. PubMed ID: 16425056
[TBL] [Abstract][Full Text] [Related]
9. In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy.
Mandema JW; Kuck MT; Danhof M
J Pharmacol Exp Ther; 1992 Apr; 261(1):56-61. PubMed ID: 1560385
[TBL] [Abstract][Full Text] [Related]
10. Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions.
Greenblatt DJ; Ehrenberg BL; Culm KE; Scavone JM; Corbett KE; Friedman HL; Harmatz JS; Shader RI
J Clin Pharmacol; 2004 Jun; 44(6):605-11. PubMed ID: 15145968
[TBL] [Abstract][Full Text] [Related]
11. Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam.
Tuk B; Herben VM; Mandema JW; Danhof M
J Pharmacol Exp Ther; 1998 Jan; 284(1):202-7. PubMed ID: 9435179
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam.
Fiset P; Lemmens HL; Egan TD; Shafer SL; Stanski DR
Clin Pharmacol Ther; 1995 Nov; 58(5):567-82. PubMed ID: 7586951
[TBL] [Abstract][Full Text] [Related]
13. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
[TBL] [Abstract][Full Text] [Related]
14. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship.
Mandema JW; Kuck MT; Danhof M
Br J Pharmacol; 1992 Jan; 105(1):164-70. PubMed ID: 1350744
[TBL] [Abstract][Full Text] [Related]
15. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil.
Mandema JW; Tukker E; Danhof M
J Pharmacol Exp Ther; 1992 Jan; 260(1):36-44. PubMed ID: 1309878
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo.
Hoyo-Vadillo C; Mandema JW; Danhof M
Life Sci; 1995; 57(4):325-33. PubMed ID: 7603305
[TBL] [Abstract][Full Text] [Related]
17. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.
Dingemanse J; van Gerven JM; Schoemaker RC; Roncari G; Oberyé JJ; van Oostenbruggen MF; Massarella J; Segala P; Zell M; Cohen AF
Br J Clin Pharmacol; 1997 Nov; 44(5):477-86. PubMed ID: 9384465
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction.
Jonker DM; Vermeij DA; Edelbroek PM; Voskuyl RA; Piotrovsky VK; Danhof M
Epilepsia; 2003 Mar; 44(3):329-38. PubMed ID: 12614388
[TBL] [Abstract][Full Text] [Related]
19. Modelling acute tolerance to the EEG effect of two benzodiazepines.
Ihmsen H; Albrecht S; Hering W; Schüttler J; Schwilden H
Br J Clin Pharmacol; 2004 Feb; 57(2):153-61. PubMed ID: 14748814
[TBL] [Abstract][Full Text] [Related]
20. Quantification of the EEG effect of midazolam by aperiodic analysis in volunteers. Pharmacokinetic/pharmacodynamic modelling.
Breimer LT; Hennis PJ; Burm AG; Danhof M; Bovill JG; Spierdijk J; Vletter AA
Clin Pharmacokinet; 1990 Mar; 18(3):245-53. PubMed ID: 2323155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
